Interferon alpha-2
Homo sapiens
State in the Current Structure
| Assembly | Oligomeric State | Construct | Mutations and Modifications | Ligands, Ions and Associated Components | Method and Experimental Conditions | Structure Quality |
|---|---|---|---|---|---|---|
| 1 | Protein heterocomplex Heteromer Protein × 2 PDB declaration: dimeric(2) Consistent with protein copy count | Chain A; UniProt 24–188 | Fragment:IFNa2 (UNP Residues 24-188) Mutation:H57A, E58A, Q61A | Interferon alpha/beta receptor 2 × 1 (P48551) | X-RAY DIFFRACTION X-ray crystallization conditions:293 K;20% (w/v) PEG 3350, 200 mM NaSCN, VAPOR DIFFUSION, HANGING DROP, temperature 293K | Resolution 2.00 Å R-free 0.233 |
| 2 | Protein heterocomplex Heteromer Protein × 2 PDB declaration: dimeric(2) Consistent with protein copy count | Chain C; UniProt 24–188 | Fragment:IFNa2 (UNP Residues 24-188) Mutation:H57A, E58A, Q61A | Interferon alpha/beta receptor 2 × 1 (P48551) CL CHLORIDE ION × 1 | X-RAY DIFFRACTION X-ray crystallization conditions:293 K;20% (w/v) PEG 3350, 200 mM NaSCN, VAPOR DIFFUSION, HANGING DROP, temperature 293K | Resolution 2.00 Å R-free 0.233 |
Other States of the Same Protein in the Database
Each row is a biological assembly of the same UniProt protein in another PDB entry. The “Difference from current entry” column identifies evidence-level differences; no tag means the currently parsed fields agree.
| Other PDB | Difference from Current Entry 3S9D | Assembly / Oligomeric State | Construct | Mutations and Modifications | Ligands, Ions and Non-polymers | Method and Experimental Conditions | Structure Quality |
|---|---|---|---|---|---|---|---|
| 1ITF INTERFERON ALPHA-2A, NMR, 24 STRUCTURES Deposited 1997-08-22 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric |
Chain A
24–188(165 aa)
|
Not recorded | No recorded non-water small molecule |
SOLUTION NMR
NMR measurement conditions
pH 3.4;298 K
|
Resolution not provided |
| 1RH2 RECOMBINANT HUMAN INTERFERON-ALPHA 2B Deposited 1996-11-07 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric |
Chain A
24–188(165 aa)
|
Not recorded | ZN ZINC ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
macroseeding;pH 5.6;PROTEIN WAS CRYSTALLIZED FROM 40MM ZINC ACETATE, 30MM CACODYLATE, PH 5.6; MACRO SEEDING WAS PERFORMED TO GET REASONABLE SIZE CRYSTALS., macroseeding
|
Resolution 2.90 Å R-free 0.311 |
| 1RH2 RECOMBINANT HUMAN INTERFERON-ALPHA 2B Deposited 1996-11-07 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric |
Chain B
24–188(165 aa)
|
Not recorded | ZN ZINC ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
macroseeding;pH 5.6;PROTEIN WAS CRYSTALLIZED FROM 40MM ZINC ACETATE, 30MM CACODYLATE, PH 5.6; MACRO SEEDING WAS PERFORMED TO GET REASONABLE SIZE CRYSTALS., macroseeding
|
Resolution 2.90 Å R-free 0.311 |
| 1RH2 RECOMBINANT HUMAN INTERFERON-ALPHA 2B Deposited 1996-11-07 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 3 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric |
Chain C
24–188(165 aa)
|
Not recorded | ZN ZINC ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
macroseeding;pH 5.6;PROTEIN WAS CRYSTALLIZED FROM 40MM ZINC ACETATE, 30MM CACODYLATE, PH 5.6; MACRO SEEDING WAS PERFORMED TO GET REASONABLE SIZE CRYSTALS., macroseeding
|
Resolution 2.90 Å R-free 0.311 |
| 1RH2 RECOMBINANT HUMAN INTERFERON-ALPHA 2B Deposited 1996-11-07 | Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 4 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric |
Chain D
24–188(165 aa)
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
macroseeding;pH 5.6;PROTEIN WAS CRYSTALLIZED FROM 40MM ZINC ACETATE, 30MM CACODYLATE, PH 5.6; MACRO SEEDING WAS PERFORMED TO GET REASONABLE SIZE CRYSTALS., macroseeding
|
Resolution 2.90 Å R-free 0.311 |
| 1RH2 RECOMBINANT HUMAN INTERFERON-ALPHA 2B Deposited 1996-11-07 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 5 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric |
Chain E
24–188(165 aa)
|
Not recorded | ZN ZINC ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
macroseeding;pH 5.6;PROTEIN WAS CRYSTALLIZED FROM 40MM ZINC ACETATE, 30MM CACODYLATE, PH 5.6; MACRO SEEDING WAS PERFORMED TO GET REASONABLE SIZE CRYSTALS., macroseeding
|
Resolution 2.90 Å R-free 0.311 |
| 1RH2 RECOMBINANT HUMAN INTERFERON-ALPHA 2B Deposited 1996-11-07 | Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 6 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric |
Chain F
24–188(165 aa)
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
macroseeding;pH 5.6;PROTEIN WAS CRYSTALLIZED FROM 40MM ZINC ACETATE, 30MM CACODYLATE, PH 5.6; MACRO SEEDING WAS PERFORMED TO GET REASONABLE SIZE CRYSTALS., macroseeding
|
Resolution 2.90 Å R-free 0.311 |
| 2HYM NMR based Docking Model of the Complex between the Human Type I Interferon Receptor and Human Interferon alpha-2 Deposited 2006-08-07 | Different construct Different mutation/modification Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric |
Chain B
24–188(165 aa)
|
Not recorded | No recorded non-water small molecule |
SOLUTION NMR
NMR measurement conditions
pH 8;308 K;Ionic strength (raw mmCIF value) 20 mM deuterated tris buffer;Pressure ambient
NMR sample composition
0.3 mM Interferon-alpha2 (D,15N), 90% D2O, 10% H2O, 20 mM deuterated tris buffer, 0.02% NaN3 | 90% D2O, 10% H2O
NMR sample composition
0.3 mM Interferon-alpha2 (D,15N, 13C), 5% D2O, 95% H2O, 20 mM deuterated tris buffer, 0.02% NaN3 | 5% D2O, 95% H2O
NMR sample composition
0.3 mM Interferon-alpha2 (D,15N), 5% D2O, 95% H2O, 20 mM deuterated tris buffer, 0.02% NaN3 | 5% D2O, 95% H2O
|
Resolution not provided |
| 2KZ1 Inter-molecular interactions in a 44 kDa interferon-receptor complex detected by asymmetric back-protonation and 2D NOESY Deposited 2010-06-10 | Different construct Different mutation/modification Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric |
Chain A
24–188(165 aa)
|
Not recorded | No recorded non-water small molecule |
SOLUTION NMR
NMR measurement conditions
pH 8;305 K;Ionic strength (raw mmCIF value) 25;Pressure ambient
NMR sample composition
0.25 mM [U-99% 2H] Interferon alpha, 0.25 mM [U-99% 2H] Soluble IFN alpha/beta receptor, 25 mM [U-2H] TRIS, 0.02 % sodium azide, 100% D2O | 100% D2O
NMR sample composition
0.25 MM [U-99% 2H, 1H-K,R,L,A,M] INTERFERON ALPHA2, 0.25 MM [U-99% 2H, 1H-H,F,W] SOLUBLE IFN ALPHA/BETA RECEPTOR, 25 mM [U-2H] TRIS, 0.02 % sodium azide, 100% D2O | 100% D2O
NMR sample composition
0.25 MM [U-99% 2H, 1H-L] INTERFERON ALPHA2, 0.25 MM [U-99% 2H, 1H-H,W] SOLUBLE IFN ALPHA/BETA RECEPTOR, 25 mM [U-2H] TRIS, 0.02 % sodium azide, 100% D2O | 100% D2O
NMR sample composition
0.25 MM [15N] INTERFERON ALPHA2, 0.25 MM [1H] SOLUBLE IFN ALPHA/BETA RECEPTOR, 25 mM [U-2H] TRIS, 0.02 % sodium azide, 95% H2O/5% D2O | 95% H2O/5% D2O
NMR sample composition
0.25 MM [1H] INTERFERON ALPHA2, 0.25 MM [15N] SOLUBLE IFN ALPHA/BETA RECEPTOR, 25 mM [U-2H] TRIS, 0.02 % sodium azide, 95% H2O/5% D2O | 95% H2O/5% D2O
|
Resolution not provided |
| 2LAG Structure of the 44 kDa complex of interferon-alpha2 with the extracellular part of IFNAR2 obtained by 2D-double difference NOESY Deposited 2011-03-13 | Different construct Different mutation/modification Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric |
Chain A
24–188(165 aa)
Fragment:Extracellular domain residues 28-237
|
Not recorded | No recorded non-water small molecule |
SOLUTION NMR
NMR measurement conditions
pH 8;305 K;Ionic strength (raw mmCIF value) 25;Pressure ambient
NMR sample composition
0.25 mM [U-99% 2H] Interferon alpha/beta receptor 2, 0.25 mM [U-99% 2H] Interferon alpha-2, 100% D2O | 100% D2O
|
Resolution not provided |
| 2LMS A single GalNAc residue on Threonine-106 modifies the dynamics and the structure of Interferon alpha-2a around the glycosylation site Deposited 2011-12-12 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric |
Chain A
24–188(165 aa)
|
Not recorded | A2G 2-acetamido-2-deoxy-alpha-D-galactopyranose × 1 |
SOLUTION NMR
NMR measurement conditions
pH 3.5;298.15 K;Ionic strength (raw mmCIF value) 25;Pressure ambient
NMR sample composition
0.85 mM [U-100% 13C; U-100% 15N] Interferon Alpha-2a (O-glycosylated), 90% H2O/10% D2O | 90% H2O/10% D2O
NMR sample composition
0.87 mM [U-100% 13C; U-100% 15N] Interferon Alpha-2a (O-glycosylated), 100% D2O | 100% D2O
|
Resolution not provided |
| 4YPG Structural Insights Into the Neutralization Properties of a Human Anti-Interferon Monoclonal Antibody Deposited 2015-03-12 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer;Protein × 3 PDB declaration: trimeric |
Chain C
24–182(159 aa)
|
Not recorded | NI NICKEL (II) ION × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 8.5;293 K;0.01 M NiCl2, 0.1 M Tris HCl
|
Resolution 3.00 Å R-free 0.272 |
| 4YPG Structural Insights Into the Neutralization Properties of a Human Anti-Interferon Monoclonal Antibody Deposited 2015-03-12 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer;Protein × 3 PDB declaration: trimeric |
Chain D
24–182(159 aa)
|
Not recorded | NI NICKEL (II) ION × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 8.5;293 K;0.01 M NiCl2, 0.1 M Tris HCl
|
Resolution 3.00 Å R-free 0.272 |
| 4Z5R Rontalizumab Fab bound to Interferon-a2 Deposited 2015-04-02 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer;Protein × 3 PDB declaration: trimeric |
Chain D
24–188(165 aa)
|
Not recorded | SO4 SULFATE ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 8.5;293 K;lithium sulfate, PEG3350, 1% dioxane
|
Resolution 3.00 Å R-free 0.251 |
| 4Z5R Rontalizumab Fab bound to Interferon-a2 Deposited 2015-04-02 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer;Protein × 3 PDB declaration: trimeric |
Chain E
24–188(165 aa)
|
Not recorded | SO4 SULFATE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 8.5;293 K;lithium sulfate, PEG3350, 1% dioxane
|
Resolution 3.00 Å R-free 0.251 |
| 4Z5R Rontalizumab Fab bound to Interferon-a2 Deposited 2015-04-02 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 3 Protein heterocomplex Heteromer;Protein × 3 PDB declaration: trimeric |
Chain F
24–188(165 aa)
|
Not recorded | SO4 SULFATE ION × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 8.5;293 K;lithium sulfate, PEG3350, 1% dioxane
|
Resolution 3.00 Å R-free 0.251 |
| 4Z5R Rontalizumab Fab bound to Interferon-a2 Deposited 2015-04-02 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 4 Protein heterocomplex Heteromer;Protein × 3 PDB declaration: trimeric |
Chain G
24–188(165 aa)
|
Not recorded | SO4 SULFATE ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 8.5;293 K;lithium sulfate, PEG3350, 1% dioxane
|
Resolution 3.00 Å R-free 0.251 |
| 4Z5R Rontalizumab Fab bound to Interferon-a2 Deposited 2015-04-02 | Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 5 Protein heterocomplex Heteromer;Protein × 3 PDB declaration: trimeric |
Chain H
24–188(165 aa)
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 8.5;293 K;lithium sulfate, PEG3350, 1% dioxane
|
Resolution 3.00 Å R-free 0.251 |
| 4Z5R Rontalizumab Fab bound to Interferon-a2 Deposited 2015-04-02 | Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 6 Protein heterocomplex Heteromer;Protein × 3 PDB declaration: trimeric |
Chain I
24–188(165 aa)
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 8.5;293 K;lithium sulfate, PEG3350, 1% dioxane
|
Resolution 3.00 Å R-free 0.251 |
| 4Z5R Rontalizumab Fab bound to Interferon-a2 Deposited 2015-04-02 | Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 7 Protein heterocomplex Heteromer;Protein × 3 PDB declaration: trimeric |
Chain X
24–188(165 aa)
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 8.5;293 K;lithium sulfate, PEG3350, 1% dioxane
|
Resolution 3.00 Å R-free 0.251 |
| 4Z5R Rontalizumab Fab bound to Interferon-a2 Deposited 2015-04-02 | Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 8 Protein heterocomplex Heteromer;Protein × 3 PDB declaration: trimeric |
Chain N
24–188(165 aa)
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 8.5;293 K;lithium sulfate, PEG3350, 1% dioxane
|
Resolution 3.00 Å R-free 0.251 |
| 9GVL type-I interferons autoantibody pmab15 in complex with Interferon alpha-2 Deposited 2024-09-25 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric |
Chain A
24–188(165 aa)
|
Not recorded | SO4 SULFATE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 4.6;291 K;0.2 M (NH4)2SO4
0.1 M NaAcetate pH 4.6
30 %w/w PEG 2000 MME
|
Resolution 2.01 Å R-free 0.270 |
| 9GVL type-I interferons autoantibody pmab15 in complex with Interferon alpha-2 Deposited 2024-09-25 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric |
Chain B
24–188(165 aa)
|
Not recorded | GOL GLYCEROL × 1 SO4 SULFATE ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 4.6;291 K;0.2 M (NH4)2SO4
0.1 M NaAcetate pH 4.6
30 %w/w PEG 2000 MME
|
Resolution 2.01 Å R-free 0.270 |
| 9GVO type-I interferons autoantibodies pmab15 and pmab14 in complex with Interferon alpha-2 Deposited 2024-09-25 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer;Protein × 3 PDB declaration: trimeric |
Chain B
24–188(165 aa)
|
Not recorded | GOL GLYCEROL × 6 PO4 PHOSPHATE ION × 2 K POTASSIUM ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 7.5;291 K;0.1 M Hepes pH 7.5
0.8 M Na2H2PO4
0.8 M KH2PO4
|
Resolution 1.81 Å R-free 0.215 |
| 9GW5 type-I interferon autoantibodies pmab3, pmab19 and pmab14 in complex with Interferon alpha-2 Deposited 2024-09-26 | Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer;Protein × 4 PDB declaration: tetrameric |
Chain A
24–188(165 aa)
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 7.5;291 K;0.1 M Hepes pH 7.5
1.9 (NH4)2SO4
|
Resolution 4.00 Å R-free 0.324 |
11 other PDB entries and 25 assemblies. Open the comparison page and filter oligomeric states
View Construct and Data Evidence
| UniProt name | IFNA2_HUMAN |
| Isoform | — |
| PDB entities | 1 |
| Chains and sequence ranges | Author chain A; PDBConstruct 4–168; UniProt 24–188 Author chain C; PDBConstruct 4–168; UniProt 24–188 |